Active — Not RecruitingNot Applicable

The DISSECT Study: Effect of Peri-aDventItial SMA diSsECtion on Margin sTatus During Pancreaticoduodenectomy for Resectable Pancreatic Cancer

United Kingdom102 participantsStarted 2021-04-06

Plain-language summary

There is a high rate of R1 resection following patients undergoing pancreaticoduodenectomy for pancreatic cancer. The most commonly positive margin is the SMA. Peri-adventitial dissection has been proposed as an effective method of achieving R0 margins. There is lack of standardisation of the proposed technique and no grade 1 evidence to support routine use of this technique. The goal of this randomised controlled trial is to investigate the role of routine peri-adventitial dissection on the SMA margin status.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. All paediatric patients (\< 18 years old)
✕. Patients that cannot provide consent
✕. All borderline, locally advanced and metastatic pancreatic tumours on imaging (based on NCCN criteria)
✕. All patients with a cytological or histological diagnosis of cholangiocarcinoma, ampullary and duodenal carcinoma
✕. All patients with benign disease or dysplasia with no evidence of malignancy

What they're measuring

SMA margin status

Timeframe: Recorded at histological examination estimated 2 weeks post-operatively

Trial details

NCT IDNCT04902352

SponsorUniversity Hospital Birmingham NHS Foundation Trust

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-10-06

View on ClinicalTrials.gov More Pancreatic Adenocarcinoma trials